Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight loss of up to 20% over 52 weeks in individuals living with obesity or overweight but without type 2 diabetes. For those with diabetes, the average weight loss reached 17%.
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback